PBAC's latest decision on Goserelin: Recommended with restriction (2017). Considered for Prevention of premature ovarian failure (POF) in pre-menopausal women undergoing treatment with alkylating agents for malignancy or autoimmune disorders.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2016
PBS spend
$53M
133,081 scripts · 2024
Eligible population
Pre-menopausal women undergoing treatment with alkylating agents (for malignancy or autoimmune disorders) at high risk of premature ovarian failure.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
This was a minor submission; no economic evaluation or ICER was conducted.
PBS expenditure
The Australian government paid $53M in PBS benefits for Goserelin in 2024 across 133,081 scripts, at $398 per script.
Submission history
Nov 2016: Deferred · Restricted
Mar 2017: Deferred · Restricted
Jul 2017: Recommended with restriction · Restricted